definiens: means the specific Antigen ( or part thereof ) coded for by reference to the sequence defined inSchedule 1 under the GD2 Program ; means all data, information, know - how and other intellectual property andresults arising from the CRUK Study including the protocol for the CRUK Study and the Test and RegulatoryData resulting from the CRUK Study ; has the meaning set out in Clause 11.1.1 ; has the meaning set out in Clause 2.2.3 ; means any product or therapy which ( i ) targets GD2 and is covered by, uses, incorporates orhas been developed using any of the GD2 Program IP ; or ( ii ) targets GD2 and has been developed using anyof the UCL Background IP or Manufacturing Know - How ; or ( iii ) were it not for the license to GD2 Program IPhereunder, would otherwise infringe any Patent Right licensed under the GD2 Program IP ; means the program of research defined in Schedule 1 under the title GD2 Program asconducted prior to the Effective Date ; has the meaning set out in Clause 6.1 ; means the program of research concerning [ * * * ] being undertaken by [ * * * ] using the [ * * * ] as isused in the [ * * * ] and any other research undertaken by [ * * * ] with respect to [ * * * ] in collaboration with [ * * * ] ineach case up to the Effective Date and thereafter during [ * * * ] Period ; means, excluding Program IP, UCL Background IP and Manufacturing Know - How, ( i ) allKnow - How and inventions generated, created or developed pursuant to the [ * * * ] Program excluding CGK as ofthe licence grant date, and ( ii ) all Patent Rights filed in respect of the research undertaken pursuant to the [ * * * ] Program ; means, excluding Manufacturing Know - How, ( i ) those patent applications listed inSchedule 2 under the title GD2 Patents and all Patent Rights derived therefrom ( ) ; ( ii ) theKnow - How described in Schedule 2 under the title GD2 Know - How ; ( iii ) the materials listed in Schedule 2 underthe title GD2 Materials together with all IP in the same ; and ( iv ) all Know - How and materials ( together with allIP in the same ) developed by MP and/or the MP Laboratory pursuant specifically to the GD2 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT . THE COPY FILEDHEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST . OMISSIONS AREDESIGNATED [ * * * ] . A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THESECURITIES AND EXCHANGE COMMISSION